Source: Eur Respir J 2014; 44: 1646-1657
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Browall Sarah, Backhaus Erik, Naucler Pontus, Galanis Ilias, Sjöström Karin, Karlsson Diana, Berg Stefan, Luthander Joachim, Eriksson Margareta, Spindler Carl, Ejdebäck Mikael, Trollfors Birger, Darenberg Jessica, Kalin Mats, Örtqvist Åke, Andersson Rune, Henriques-Normark Birgitta. Clinical manifestations of invasive pneumococcal disease by vaccine and non-vaccine types. Eur Respir J 2014; 44: 1646-1657

Member's Comments

No comment yet.

Related content which might interest you: The remaining challenges of pneumococcal disease in adults Source: Eur Respir Rev 2012; 21: 57-65 Year: 2012 Invasive pneumococcal disease (IPN) and pneumococcal vaccination in our setting Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015 Clinical presentations and serotypes causing invasive pneumococcal disease in adults vaccinated with the 23-valent polysaccharide pneumococcal vaccine (PPV23) in Spain. The ODIN study (2010-2013) Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer Year: 2014 Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden Source: Eur Respir J 2016; 47: 1208-1218 Year: 2016 Evolutionary trend of invasive pneumococcal disease according to serotypes Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine Source: Eur Respir J 2013; 42: 1595-1603 Year: 2013 No preventive effects of 23-valent pneumococcal polysaccharide vaccine in patients with chronic renal failure Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Clinical evolution of patients with COPD after administration of 23-valent pneumococcal capsular polysacharide vaccine (PCPV) Source: Eur Respir J 2005; 26: Suppl. 49, 286s Year: 2005 Immunity to pneumococcal disease Source: Annual Congress 2013 –New understanding of pneumococcal vaccination Year: 2013 Impact of pneumococcal vaccination in children in the distribution of serotypes in bacteriemic pneumococcal pneumonia in adults Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 Pneumococcal polysaccharide vaccination in COPD patients - some problems with antibody-response Source: Eur Respir J 2002; 20: Suppl. 38, 472s Year: 2002 Should pneumococcal vaccines be used to prevent LRTI? Source: Annual Congress 2009 - PG1 EU GRACE Network Full-day Course: vaccination and preventive measures for LRTIs in the community: what’s new? Year: 2009 Effects of pneumococcal vaccine in patients with chronic respiratory disease Source: Eur Respir Rev 2008; 17: 43-45 Year: 2008 Effects of pneumococcal vaccine in patients with chronic respiratory disease Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007 Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia Source: Eur Respir J 2015; 45: 1632-1641 Year: 2015 Indication of pneumococcal vaccination in CF patients Source: Eur Respir J 2001; 18: Suppl. 33, 539s Year: 2001 Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly Source: Eur Respir J 2010; 36: 608-614 Year: 2010 Influenza and pneumococcal vaccination in patients with COPD Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020